labetalol has been researched along with Aging in 12 studies
Labetalol: A salicylamide derivative that is a non-cardioselective blocker of BETA-ADRENERGIC RECEPTORS and ALPHA-1 ADRENERGIC RECEPTORS.
labetalol : A diastereoisomeric mixture of approximately equal amounts of all four possible stereoisomers ((R,S)-labetolol, (S,R)-labetolol, (S,S)-labetalol and (R,R)-labetalol). It is an adrenergic antagonist used to treat high blood pressure.
2-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide : A member of the class of benzamides that is benzamide substituted by a hydroxy group at position 2 and by a 1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl group at position 5.
Aging: The gradual irreversible changes in structure and function of an organism that occur as a result of the passage of time.
| Excerpt | Relevance | Reference |
|---|---|---|
| " placebo added to hydrochlorothiazide (HCTZ) for the treatment of essential hypertension." | 9.05 | Labetalol and hydrochlorothiazide in hypertension. Labetalol/Hydrochlorothiazide Multicenter Study Group. ( , 1985) |
| "The effectiveness of repeated intravenous injections of labetalol in reducing blood pressure (BP) was evaluated in patients with severe hypertension." | 7.66 | Treatment of severe hypertension with intravenous labetalol. ( Freis, ED; Khatri, IM; Notargiacomo, AV; Papademetriou, V, 1982) |
| "Twenty young (45 years or younger) and 20 older (55 years or older) adult patients with mild hypertension were enrolled in this study to compare the hemodynamic effects of labetalol versus placebo in two age groups." | 5.06 | Hemodynamic effects of labetalol in young and older adult hypertensives. ( Buell, JC; Eliot, RS; Little, MR; Plachetka, JR, 1988) |
| " placebo added to hydrochlorothiazide (HCTZ) for the treatment of essential hypertension." | 5.05 | Labetalol and hydrochlorothiazide in hypertension. Labetalol/Hydrochlorothiazide Multicenter Study Group. ( , 1985) |
| "Labetalol is an alpha 1- and beta-adrenergic antagonist currently used in the treatment of hypertension." | 3.67 | Effects of age on the elimination of labetalol. ( Rocci, ML; Sirgo, MA; Valiquett, T, 1989) |
| "The effectiveness of repeated intravenous injections of labetalol in reducing blood pressure (BP) was evaluated in patients with severe hypertension." | 3.66 | Treatment of severe hypertension with intravenous labetalol. ( Freis, ED; Khatri, IM; Notargiacomo, AV; Papademetriou, V, 1982) |
| "Carvedilol is a new beta-blocker antihypertensive agent with vasodilating properties secondary to alpha 1-blocking activity." | 2.40 | Results of therapy with carvedilol, a beta-blocker vasodilator with antioxidant properties, in hypertensive patients. ( Frishman, W; Moser, M, 1998) |
| " There was a significant increase with age in both bioavailability and half-life of labetalol." | 1.26 | Bioavailability of labetalol increases with age. ( Kelly, JG; McGarry, K; O'Brien, ET; O'Malley, K, 1982) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 10 (83.33) | 18.7374 |
| 1990's | 2 (16.67) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Scriven, AJ | 1 |
| Lewis, PJ | 1 |
| Koch, G | 1 |
| Barousch, R | 1 |
| Kelly, JG | 1 |
| McGarry, K | 1 |
| O'Malley, K | 1 |
| O'Brien, ET | 1 |
| Papademetriou, V | 1 |
| Notargiacomo, AV | 1 |
| Khatri, IM | 1 |
| Freis, ED | 1 |
| Moser, M | 1 |
| Frishman, W | 1 |
| Elliott, HL | 1 |
| Macphee, GJ | 1 |
| Meredith, PA | 1 |
| Messerli, FH | 1 |
| Rocci, ML | 1 |
| Valiquett, T | 1 |
| Sirgo, MA | 1 |
| Buell, JC | 1 |
| Eliot, RS | 1 |
| Plachetka, JR | 1 |
| Little, MR | 1 |
| Seal, DV | 1 |
4 reviews available for labetalol and Aging
| Article | Year |
|---|---|
Beta-adrenergic blocking drugs in the treatment of hypertension.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aging; Black People; Drug Interactions; Heart; Hemodynamic | 1983 |
Hemodynamic changes after acute and long-term combined alpha--beta-adrenoceptor blockade with labetalol as compared with beta-receptor blockade.
Topics: Adolescent; Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Aged; Aging; Ethanolam | 1981 |
Results of therapy with carvedilol, a beta-blocker vasodilator with antioxidant properties, in hypertensive patients.
Topics: Adrenergic beta-Antagonists; Aging; Antioxidants; Blood Pressure; Carbazoles; Carvedilol; Humans; Hy | 1998 |
Hemodynamic and cardiac adaptation in essential hypertension. Consequences for therapy.
Topics: Adaptation, Physiological; Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Aging; Black People | 1985 |
3 trials available for labetalol and Aging
| Article | Year |
|---|---|
The influence of age on the pharmacokinetics and antihypertensive responses to dilevalol.
Topics: Adult; Aged; Aging; Female; Hemodynamics; Humans; Hypertension; Labetalol; Male; Middle Aged | 1990 |
Labetalol and hydrochlorothiazide in hypertension. Labetalol/Hydrochlorothiazide Multicenter Study Group.
Topics: Administration, Oral; Adult; Aged; Aging; Analysis of Variance; Blood Pressure; Clinical Trials as T | 1985 |
Hemodynamic effects of labetalol in young and older adult hypertensives.
Topics: Adult; Aging; Blood Pressure; Cardiac Output; Dosage Forms; Heart Rate; Humans; Hypertension; Labeta | 1988 |
5 other studies available for labetalol and Aging
| Article | Year |
|---|---|
[Experiences with Trandate in geriatrics].
Topics: Aged; Aging; Drug Evaluation; Ethanolamines; Female; Humans; Hypertension; Labetalol; Male | 1981 |
Bioavailability of labetalol increases with age.
Topics: Adult; Aged; Aging; Biological Availability; Ethanolamines; Half-Life; Humans; Labetalol; Middle Age | 1982 |
Treatment of severe hypertension with intravenous labetalol.
Topics: Adult; Aging; Dose-Response Relationship, Drug; Ethanolamines; Heart Rate; Humans; Hypertension; Inj | 1982 |
Effects of age on the elimination of labetalol.
Topics: Adult; Aged; Aging; Female; Humans; Hypertension; Labetalol; Male; Middle Aged | 1989 |
The effect of ageing and disease on tear constituents.
Topics: Adult; Aged; Aging; Blepharitis; Ceruloplasmin; Eyelid Diseases; Humans; Immunoglobulin A; Immunoglo | 1985 |